Matthew Feldman, MD
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $16,907 with a category attached, or 88.7%. Boston Scientific accounts for 89.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $7,595 and has fallen 82.9% since, to $1,297 in 2025.
Across 24 payments — averaging $704.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Bayer$1K
- Amneal Pharmaceuticals LLC$160
- Neurelis, Inc.$117
- UCB, Inc.$111
- Impel Pharmaceuticals Inc.$21
- plus $19 from 1 others
What the payments were for
- Grants$15,00089%
- Travel & lodging$9946%
- Food & beverage$9135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $15,201 |
| Bayer | 9 | $1,278 |
| Amneal Pharmaceuticals LLC | 2 | $160 |
| Neurelis, Inc. | 2 | $117 |
| UCB, Inc. | 3 | $111 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,907 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 78 | $1,848 |
| Rasagiline Mesylate | 15 | $999 |
| RivastigmineRivastigmine Tartrate | 23 | $945 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 18 | $587 |
| Gabapentin | 14 | $144 |
Paid to pharmacies, not to this prescriber.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.